向特定对象发行股票的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》等 相关规定，大连百傲化学股份有限公司（以下简称"公司"）于2025年4月24日 召开第五届董事会第十二次会议，审议通过了《关于提请股东大会授权董事会以 简易程序向特定对象发行股票的议案》。公司董事会提请股东大会授权董事会办 理以简易程序向特定对象发行股票（以下简称"本次发行"）相关事宜，授权期 限自2024年年度股东大会审议通过之日起至2025年年度股东大会召开之日止。现 将有关情况公告如下： 一、本次授权事宜 （一）确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会根据相关法律、法规、规范性文件以及《公司章程》的规定，对 公司实际情况及相关事项进行自查论证，并确认公司是否符合以简易程序向特定 对象发行股票的条件。 证券代码：603360 证券简称：百傲化学 公告编号：2025-037 大连百傲化学股份有限公 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,311,701,965.84, representing a 23.09% increase compared to ¥1,065,660,659.85 in 2023[25] - The net profit attributable to shareholders for 2024 was ¥345,256,428.77, a 5.14% increase from ¥328,375,064.55 in 2023[25] - The basic earnings per share for 2024 was ¥0.68, up 3.03% from ¥0.66 in 2023[27] - The net profit after deducting non-recurring gains and losses for 2024 was ¥320,487,172.86, slightly up by 0.49% from ¥318,914,019.48 in 2023[25] - The total equity attributable to shareholders increased by 9.27% to ¥1,788,474,436.44 at the end of 2024, compared to ¥1,636,719,076.66 at the end of 2023[26] - The company’s industrial biocide business generated revenue of CNY 1,207,089,076.19, with a gross margin of 44.30%, which decreased by 8.28 percentage points compared to the previous year[53] - The semiconductor business generated revenue of ¥97,781,410.39 with a gross margin of 43.38%[54] - Domestic revenue reached ¥543,282,552.03, up 20.50% year-over-year, while the gross margin decreased by 7.62 percentage points to 42.34%[54] - International revenue was ¥761,587,934.55, an increase of 26.20% year-over-year, with a gross margin of 45.58%, down 8.95 percentage points[54] Cash Flow and Assets - The net cash flow from operating activities decreased by 58.18% to ¥162,979,875.46 in 2024, down from ¥389,685,710.62 in 2023[25] - Total assets increased by 87.45% to ¥3,639,769,869.79 at the end of 2024, compared to ¥1,941,704,269.90 at the end of 2023[26] - The company reported a net cash flow from operating activities of -537.17 million RMB in Q1, followed by positive cash flows in subsequent quarters[29] - Accounts receivable increased by 144.08% to 342,044,792.01 RMB compared to the previous period, primarily due to the acquisition of the subsidiary Chipwise[67][68] - Prepayments surged by 536.32% to 353,918,126.63 RMB, mainly attributed to advances for semiconductor equipment following the acquisition of Chipwise[67][68] Research and Development - The company maintained R&D investment at over 3% of operating revenue, focusing on chemical and semiconductor sectors[33] - Research and development expenses increased by 27.39% to CNY 49,655,454.39, reflecting the company's commitment to innovation[51] - The company has applied for and obtained 57 patents in semiconductor technology, enhancing its innovation capabilities[47] - The company has developed over 50 formula products, with more than 30 currently on sale, which have higher sales prices and gross profit margins compared to raw materials[95] - Research and development investments over the past three years were 47.14 million, 38.98 million, and 47.10 million CNY, representing 3.75%, 3.66%, and 3.89% of revenue respectively, indicating a sustained high level of R&D spending[94] Strategic Initiatives - The company has strategically entered the semiconductor industry, completing a strategic acquisition of semiconductor equipment company Chipwise by the end of 2024, marking a successful cross-industry merger under new policy frameworks[36] - The company plans to invest CNY 700 million in its subsidiary, Xin Hui Lian Semiconductor Technology Co., Ltd., to gain a controlling stake of 54.6342%[51] - The company plans to focus on industrial biocides and semiconductor sectors, aiming to enhance global competitiveness and achieve high-quality development by 2025[98] - The company plans to establish wholly-owned subsidiaries and engage in strategic partnerships in the semiconductor sector[125] - The company has signed a cooperation agreement with Suzhou Xinhuilian Semiconductor Technology Co., Ltd. for semiconductor equipment business in December 2024[117] Risk Management - The company has indicated potential risks related to future plans and industry trends, advising investors to be cautious[7] - The company has established a differentiated management framework to enhance risk control and governance efficiency[33] - The company faces risks from fluctuations in raw material prices, including octylamine, methyl acrylate, magnesium nitrate, ethyl acetate, and chlorine, which may impact operational efficiency[100] - The semiconductor equipment industry is highly technology-intensive, and failure to keep pace with technological advancements may lead to a decline in market competitiveness[100] - The company is at risk of losing core technical personnel due to increasing competition for skilled talent in the semiconductor equipment sector[100] Governance and Management - The company has a diverse management team with extensive experience in various sectors, enhancing its strategic decision-making capabilities[106] - The board includes independent directors with backgrounds in law and finance, contributing to governance and oversight[106] - The company has experienced a complete turnover of its fourth board of directors, with all members leaving due to the expiration of their terms[112] - The remuneration decision process for directors and senior management is based on industry standards and company performance metrics[111] - The company has ensured that all remuneration payments to directors and senior management have been completed as per the established guidelines[111] Environmental and Compliance - The company is committed to environmental protection and has invested in high-standard facilities to comply with regulations, which may increase operational costs[99] - The company has completed the environmental management system re-examination and certification in April 2024[157] - The company has not faced any administrative penalties related to environmental issues during the reporting period[157] - The company’s environmental monitoring plan includes regular third-party testing, with all results meeting the required standards[156] - The company has not disclosed a separate social responsibility report or ESG report[161] Shareholder and Capital Structure - The company plans to distribute a cash dividend of ¥6.00 per 10 shares, totaling approximately ¥302,667,280.20, and issue 4 bonus shares for every 10 shares held, increasing the total share capital from 504,445,467 shares to 706,223,654 shares[6] - The total share capital increased to 504,445,467 shares after a bonus issue of 144,127,276 shares, representing a 39.9% increase[178] - The cumulative cash dividends over the last three accounting years amount to CNY 721,876,177.20, with an average net profit of CNY 358,732,337.08, resulting in a cash dividend ratio of 201.23%[136] - The company has established a shareholder return plan for the next three years (2023-2025), committing to distribute at least 20% of the distributable profits as cash dividends when the audited net profit is positive[131] - The largest shareholder, Dalian Tongyun Investment Co., Ltd., holds 151,129,657 shares, representing 29.96% of total shares[186]

大连百傲化学股份有限公司 二〇二四年度 审计报告 致同会计师事务所（特殊普通合伙） 目 录 | 审计报告 | 1-6 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-105 | 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 审计报告 致同审字（2025）第 210A017357 号 大连百傲化学股份有限公司全体股东： 一、审计意见 我们审计了大连百傲化学股份有限公司（以下简称百傲化学公司）财务 报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及 公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关 财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了百傲化学公司 20 ...

大连百傲化学股份有限公司 二〇二四年度 内部控制审计报告 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效 性是百傲化学公司董事会的责任。 致同会计师事务所（特殊普通合伙） t Thornton 20 日 内部控制审计报告 致同审字(2025)第 210A017358 号 大连百傲化学股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了大连百傲化学股份有限公司(以下简称百傲化学公司)2024年12 月 31 目的财务报告内部控制的有效性。 我们认为,百傲化学公司于 2024年 12月 31日按照《企业内部控制基本 规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 中国社 # 中国注册会计师 中国注册会计 二〇二五年四月二十四日 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性 发表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现 ...

关于大连百傲化学股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：大连百傲化学股份有限公司 审计单位：致同会计师事务所（特殊普通合伙） 联系电话：0411-82285231 关于大连百傲化学股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所(特殊普通合伙) 您可使用于机"扫一扫"或进入"注册会计算行业线一监管平台（brqs//accgrol.gov.cn)。" 您可使用于机"扫一扫"或进入"注册会计算行业按一监管平台（brqs//acc.grg.cn)。2018官登录 目 录 关于大连百微化学股份有限公司考经营性资金占用及其他关联赛 金在来的专项说明 大连百家化学股份有限公司 2024年度春级营饮资金占用及其他关 联资会往来情况汇总表 关于大连百微化学股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字(2025) 第210A010387 号 大连百做化学股份有限公司全体股东1 我们接受大连百傲化学股份有限公司(以下简称百傲化学公司) 委托, 根据中国注册会计师执业准则审计了百傲化学公司 2 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 448.32 million, representing a year-on-year increase of 32.54% compared to CNY 338.25 million in the same period last year[4]. - Net profit attributable to shareholders decreased by 48.98% to CNY 50.16 million from CNY 98.31 million year-on-year[4]. - The basic earnings per share fell by 47.37% to CNY 0.10, down from CNY 0.19 in the previous year[4]. - Total operating revenue for Q1 2025 reached ¥448.32 million, a 32.6% increase from ¥338.25 million in Q1 2024[16]. - Net profit for Q1 2025 was ¥59.99 million, a decrease of 39.0% compared to ¥98.31 million in Q1 2024[17]. - The company reported a total comprehensive income of ¥60.17 million for Q1 2025, down from ¥96.12 million in Q1 2024[17]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.10, compared to ¥0.19 in Q1 2024[17]. Assets and Liabilities - The total assets at the end of the reporting period increased by 7.40% to CNY 3.91 billion from CNY 3.64 billion at the end of the previous year[5]. - As of March 31, 2025, the total current assets amounted to RMB 2,651,596,604.90, an increase from RMB 2,513,034,095.85 as of December 31, 2024, reflecting a growth of approximately 5.5%[12]. - The company's total equity increased to RMB 2,417,535,762.23 from RMB 2,351,197,323.20, reflecting a growth of approximately 2.8%[13]. - Total liabilities as of March 31, 2025, were RMB 1,491,485,198.98, compared to RMB 1,288,572,546.59 at the end of 2024, marking an increase of around 15.7%[13]. - Short-term borrowings rose to RMB 524,194,769.38 from RMB 423,937,895.84, indicating an increase of about 23.6%[13]. - The accounts receivable decreased to RMB 304,607,607.48 from RMB 342,044,792.01, showing a decline of approximately 10.9%[12]. - The company reported a decrease in contract liabilities from RMB 347,910,486.36 to RMB 226,842,838.22, a reduction of about 34.7%[13]. Cash Flow and Expenses - The net cash flow from operating activities was negative at CNY -59.64 million, worsening by 11.04% compared to CNY -53.72 million in the previous year[4]. - Cash flow from operating activities for Q1 2025 was negative at -¥59.64 million, compared to -¥53.72 million in Q1 2024[21]. - The company incurred a financial expense of ¥2.01 million in Q1 2025, compared to a financial income of -¥2.86 million in Q1 2024[16]. - Research and development expenses increased to ¥18.70 million in Q1 2025, up 80.6% from ¥10.34 million in Q1 2024[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,656[8]. - Major shareholder Dalian Tongyun Investment Co., Ltd. holds 29.96% of shares, with 20 million shares pledged[9]. Other Financial Metrics - The weighted average return on equity decreased by 3.06 percentage points to 2.77% from 5.83% year-on-year[4]. - The semiconductor business achieved a revenue of CNY 260 million, a year-on-year increase of 389.39% and a quarter-on-quarter increase of 35.19%[7]. - The company's cash and cash equivalents reached RMB 845,334,296.97, up from RMB 668,244,186.44, indicating a significant increase of about 26.5%[11]. - Inventory levels increased to RMB 937,607,900.95 from RMB 902,353,613.16, representing a rise of approximately 3.9%[12]. - The long-term investments in equity stood at RMB 122,827,058.57, with no previous figure provided for comparison[12]. - The company maintained a stable goodwill value of RMB 230,532,246.93, unchanged from the previous reporting period[12]. - The company experienced a foreign exchange gain of ¥1.68 million in Q1 2025, compared to a gain of ¥0.78 million in Q1 2024[22].

百傲化学（603360）公告，2024年营业收入13.12亿元，同比增长23.09%。归属于上市公司股东的净利 润3.45亿元，同比增长5.14%。拟以未来实施利润分配方案时确定的股权登记日的总股本为基数，向全 体股东每10股派发现金红利6元(含税)，以此计算合计拟派发现金红利3.03亿元(含税)；拟向全体股东每 10股派送红股4股，合计送股股数2.02亿股(送股股数系根据实际计算结果四舍五入所得，最终送股的准 确数量以中国证券登记结算有限责任公司上海分公司实际登记确认的为准)，送股后股本总数由5.04亿 股增至7.06亿股，同日公告，拟2亿元-4亿元回购股份。 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 大连百傲化学股份有限公司 王文亚先生在担任公司监事期间，恪尽职守、勤勉尽责，为公司的规范运作 和健康发展发挥了积极作用。公司监事会对王文亚先生为公司发展所作出的贡献 表示衷心感谢！ 关于监事辞职的公告 特此公告。 大连百傲化学股份有限公司（以下简称"公司"）监事会于 2025 年 4 月 18 日收到非职工代表监事王文亚先生的辞职报告，王文亚先生因公司第二大股东大 连光曜致新舒鸿企业管理咨询合伙企业（有限合伙）的合伙人结构变动、本人任 职单位中国东方资产管理股份有限公司已从该合伙企业退伙的原因，申请辞去公 司非职工代表监事职务，辞职后不再担任公司任何职务。 王文亚先生辞职将导致公司监事会人数低于规定人数，公司将按照有关规定， 尽快完成非职工代表监事的补选工作，在此之前，王文亚先生将继续履行监事职 责。 证券代码：603360 证券简称：百傲化学 公告编号：2025-022 大连百傲化学股份有限公司监事会 2025 年 4 月 19 日 ...

大连百傲化学（603360）股份有限公司(以下简称"百傲化学")的半导体设备业务正快马加鞭，加速推 进。 对于此次任命，百傲化学在公告中表示，鉴于公司主要业务将由化工业务逐步扩展至化工和半导体业 务，为满足战略发展需要，进一步提高运营管理效率，明晰内控治理体系，逐渐形成化工、半导体两大 业务板块各自独立发展的经营格局。刘红军将负责管理公司半导体业务板块。 值得注意的是，百傲化学此前并未设置有联席总经理职位。为了此次管理层架构调整，百傲化学还同步 修订公司章程，明确联席总经理与总经理拥有同等权利和义务。 公开披露的简历信息显示，刘红军在半导体设备领域履历丰富，是一名行业老将。其曾任东电光电半导 体设备(昆山)有限公司总监，北京亦盛精密半导体有限公司总经理，现任芯慧联董事长以及芯慧联新(苏 州)科技有限公司(以下简称"芯慧联新")董事长。 2024年，百傲化学先是通过与芯慧联的牵手合作进入半导体设备行业，后又通过对拆分后存续的芯慧联 公司的收购进一步完善在半导体领域的业务布局。如今，百傲化学已成为涉足涂胶显影机、光刻机等黄 光制程设备、湿法清洗设备、半导体产线用自动化设备、晶圆混合键合设备等多个领域的半导体设备制 ...

经济观察报记者黄一帆4月10日，处于向半导体业务转型关键期的百傲化学（603360）(603360.SH)围绕 自身半导体布局发布多份公告。 据公告，百傲化学董事会聘任刘红军担任公司联席总经理并提名非独立董事，负责管理公司半导体业务 板块。 此外，百傲化学还披露了控股子公司苏州芯慧联半导体科技有限公司(以下简称"芯慧联")在无锡锡东新 城商务区的半导体设备生产基地的建设、对下属控股公司增资与珠三角的布局等事项。 2024年，百傲化学通过收购芯慧联进入半导体设备行业。目前，百傲化学正加速该新业务领域布局。 据了解，刘红军执掌的芯慧联新主要聚焦于晶圆键合设备领域。 百傲化学方面告诉经济观察报，键合设备是芯片制造的核心环节，此前这一市场被国际巨头垄断。 2024年11月，芯慧联新出货2台混合键合设备，这2台设备刷新了国内该系列设备的精度水平。据公开信 息，百傲化学参股了芯慧联新。 启动半导体设备基地建设 除公告上述重要人事安排外，百傲化学还披露半导体设备基地的建设情况。 "老将"刘红军拟任联席总经理 在贸易争端的大背景下，半导体设备的自主可控是目前亟待解决的棘手问题。期间，多家上市公司参与 到产业链的各个环节，其中 ...